Reditux 500 mg Rituximab Injection (1 vial / 50 mL)

At a Glance

Generic Name: Rituximab

Brand Name: Reditux 500 mg

Strength & Pack Size: 500 mg rituximab in 50 mL, 1 single-use vial

Dosage Form & Route: Sterile concentrate for solution for IV infusion after dilution

Therapeutic Class: CD20-targeted chimeric monoclonal antibody (biologic / biosimilar)

Primary Indications: CD20-positive non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis and ANCA-associated vasculitis (where approved)

Typical Use in Therapy: Given in cycles or courses, often alongside chemotherapy or immunosuppressive regimens in specialist infusion centres

Mode of Action: Binds CD20 on B lymphocytes and triggers immune-mediated B-cell depletion

Key Benefits: Proven improvements in response and disease control across multiple CD20-positive malignancies and autoimmune diseases when used according to guidelines

Precautions: Risk of serious infusion reactions, infections, HBV reactivation and rare PML; requires screening, premedication and close monitoring

Storage: Keep refrigerated at 2–8 °C in the original carton, protect from light, do not freeze

Product Description

Reditux 500 mg is a rituximab injection supplied as a 500 mg/50 mL single-use vial of CD20-targeted monoclonal antibody concentrate for solution for infusion. Rituximab has transformed the management of many B-cell malignancies and immune-mediated diseases by selectively depleting CD20-expressing B lymphocytes. As a rituximab biosimilar, Reditux 500 mg rituximab injection is designed to offer comparable quality, safety and efficacy to reference rituximab when used in line with approved indications and specialist protocols.

Reditux 500 mg rituximab injection is used in CD20-positive non-Hodgkin lymphoma, chronic lymphocytic leukemia and selected autoimmune conditions such as rheumatoid arthritis and ANCA-associated vasculitis. In oncology, it is usually combined with standard chemotherapy backbones and given in repeated cycles or maintenance courses. In autoimmune diseases, it is used as an advanced biologic option when conventional disease-modifying therapies or TNF inhibitors have not provided adequate control. In all cases, treatment planning, dosing and monitoring are the responsibility of experienced haematologists, oncologists or rheumatologists.

Generic Meds Mart sources Reditux 500 mg rituximab injection exclusively from licensed manufacturers and authorised distributors that follow Good Manufacturing Practice and maintain full batch traceability. Vials are supplied in original refrigerated packaging, and orders are shipped in neutral outer boxes so that there is no visible reference to lymphoma, leukemia or autoimmune disease on the parcel. Where available, shipments include tracking to help infusion centres coordinate appointment scheduling. Our role is limited to access and logistics; all clinical decisions about whether and how to use rituximab remain with your specialist team.

Key Uses

Reditux 500 mg rituximab injection is generally used for the following indications, in line with local prescribing information and established guidelines:

Reditux 500 mg is widely used in CD20-positive non-Hodgkin lymphoma, including indolent and aggressive B-cell subtypes, as part of combination chemotherapy regimens and sometimes as maintenance therapy. In chronic lymphocytic leukemia (CLL), rituximab is often combined with chemotherapy or targeted agents in patients whose leukemic cells express CD20.

Outside oncology, rituximab is used in moderate to severe rheumatoid arthritis in adults with active disease who have had an inadequate response or intolerance to one or more TNF inhibitors. It is also used in ANCA-associated vasculitis, including granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), where B-cell depletion forms an important component of induction and maintenance strategies in many treatment protocols.

The decision to use Reditux 500 mg, the dosing schedule and the number of vials required per course are all defined by the treating specialist based on body size, diagnosis, disease burden, prior therapies, comorbidities and treatment goals.

How Rituximab Works in Chemotherapy

Rituximab, the active ingredient in Reditux 500 mg, is a chimeric monoclonal antibody directed against the CD20 antigen on B lymphocytes. CD20 is expressed on most normal and malignant B cells from early pre-B stages through to mature B cells, but not on stem cells or plasma cells. This pattern allows selective depletion of circulating and tissue B cells while preserving regenerative capacity and long-lived plasma cells.

When Reditux 500 mg rituximab injection is infused, rituximab binds to CD20 on the surface of B cells and “flags” them for destruction through several immune mechanisms. Antibody-dependent cellular cytotoxicity recruits effector cells such as natural killer cells to attack rituximab-coated B cells. Complement-dependent cytotoxicity activates the complement cascade, which leads to membrane attack complex formation and cell lysis. Rituximab can also trigger direct apoptotic signalling within CD20-positive cells.

By reducing malignant or autoreactive B-cell populations, rituximab helps shrink CD20-positive lymphomas and leukemias and can reset dysregulated humoral immunity in autoimmune diseases. Over time, B cells typically repopulate after treatment, and the timing of this recovery depends on dose, regimen, concomitant therapies and individual factors.

Dosage & Administration

Reditux 500 mg rituximab injection must only be prescribed and administered by physicians experienced in oncology, haematology or rheumatology, in settings that can manage serious infusion reactions. The 500 mg/50 mL vial is never given undiluted. Instead, the concentrate is diluted into a compatible infusion solution and administered intravenously over several hours.

Patients are typically premedicated with corticosteroids, antihistamines and antipyretics to reduce the risk of infusion-related reactions such as fever, chills, rigors or bronchospasm. The first infusion is usually started slowly and escalated stepwise under continuous monitoring; if tolerated, subsequent infusions may be given at higher rates. Dosing regimens may be expressed in mg/m² or as fixed milligram doses depending on the indication, and treatment may involve induction and maintenance phases or repeated cycles tied to chemotherapy.

The exact number of Reditux 500 mg vials per infusion, the interval between infusions and the total treatment duration must follow the official product information and your specialist’s protocol. Patients should never attempt to adjust rituximab dose, frequency or infusion speed on their own.

Precautions

Before starting Reditux 500 mg, your clinician will review your medical history, physical examination, organ function, vaccination records and infection risk. Screening for hepatitis B virus (HBV) is usually performed because rituximab can cause HBV reactivation in previously exposed patients, which may be life-threatening. The team will also consider tuberculosis, other chronic infections and recent or planned vaccinations.

Because rituximab is associated with serious infusion reactions and immunosuppression, Reditux 500 mg should be administered only in facilities that can respond rapidly to acute reactions and monitor patients closely. Live vaccines are typically avoided during and shortly after rituximab therapy, and inactivated vaccines may be less effective. Contraception is strongly recommended during therapy and for a period afterwards, since rituximab can affect fetal B-cell development and neonatal immune status if given during pregnancy.

Rituximab Side Effects

Common side effects

Common rituximab side effects observed with Reditux 500 mg include infusion-related symptoms such as fever, chills, rigors, headache, flushing, mild shortness of breath, itching or rash during or shortly after the infusion. Many patients also report fatigue, nausea, mild abdominal discomfort, temporary blood pressure changes and transient reductions in white blood cell or platelet counts. These effects are often manageable by adjusting the infusion rate, providing supportive medicines and optimising premedication for subsequent infusions.

Serious side effects

Serious rituximab adverse effects require urgent medical attention. These include severe infusion reactions with bronchospasm, marked breathing difficulty, chest pain, angio-oedema, hypotension or anaphylaxis; severe infections and sepsis; hepatitis B virus reactivation with potentially fatal liver failure; progressive multifocal leukoencephalopathy (PML) presenting with new or worsening neurological symptoms; severe mucocutaneous reactions such as Stevens–Johnson syndrome and toxic epidermal necrolysis; tumour lysis syndrome in high tumour burden states; and serious cardiac events in susceptible patients.

Patients should be advised to seek immediate medical care if they experience high fever, severe weakness, confusion, visual changes, difficulty speaking, severe rash, peeling skin, marked jaundice, chest pain or acute breathing difficulties during or after Reditux 500 mg rituximab injection treatment.

Storage

Reditux 500 mg vials must be stored in a refrigerator at 2–8 °C in their original carton to protect from light and physical damage. The solution must not be frozen or shaken. Storage, preparation and disposal are usually handled by hospital pharmacies or infusion centres that maintain cold-chain records and follow local guidelines for biologic and cytotoxic waste. Once diluted, the prepared rituximab infusion solution has specific in-use stability limits, and it must be prepared and administered according to the product information and institutional policies.

Why Buy from Generic Meds Mart

Generic Meds Mart is focused on structured access to essential oncology and immunology biologics such as Reditux 500 mg rituximab injection. We work only with licensed manufacturers and authorised distributors that comply with Good Manufacturing Practice standards and maintain verifiable batch documentation. Each 500 mg/50 mL vial is supplied in sealed original packaging so infusion centres can confirm brand, strength, batch number and expiry before preparation.

Prices are shown in USD to make budgeting for repeated cycles or maintenance courses more transparent. Orders are shipped in discreet outer boxes without references to lymphoma, leukemia or autoimmune disease, and where available, tracking is provided so that treatment teams can synchronise appointments with expected delivery dates. Our customer support can help with ordering and logistics queries, but we do not provide medical advice; all clinical decisions about rituximab use remain with your specialist team.

Order Now

Reditux 500 mg rituximab injection is a potent, hospital-only biologic that must not be started without a clear treatment plan. Before ordering from Generic Meds Mart, you should discuss rituximab with your haematologist, oncologist or rheumatologist and receive written guidance on indication, CD20 status, dosing schedule, infusion setting, premedication and monitoring requirements.

Once your plan is agreed, your team can calculate how many vials of Reditux 500 mg (1 vial / 50 mL) are needed for the initial cycles or maintenance period. You can then select the required quantity on Generic Meds Mart, add it to your cart and complete secure checkout in USD. Your medicines will be dispatched in discreet packaging with full product documentation. You should never start, stop, delay or change rituximab therapy without consulting your specialist, and any new, severe or concerning symptoms should prompt immediate medical review.

FAQ about Reditux (Rituximab)

Q1: What conditions is Reditux 500 mg used to treat?
Reditux 500 mg contains rituximab, a CD20-targeted monoclonal antibody used in CD20-positive non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis and ANCA-associated vasculitis such as granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), according to local approvals and guidelines.

Q2: Is Reditux 500 mg given as a drip or an injection?
Reditux 500 mg rituximab injection is a concentrate for solution for infusion. The 500 mg/50 mL vial is diluted into a larger volume of compatible solution and given as an intravenous drip over several hours in a hospital or infusion centre; it is not injected as a rapid IV push or routine subcutaneous shot.

Q3: How long does a typical Reditux infusion take?
The first Reditux 500 mg rituximab infusion is usually administered very slowly and can take several hours, as the infusion rate is gradually increased while staff monitor for reactions. If tolerated, later infusions may be faster, but exact timing depends on the indication, prescribed dose and your individual tolerance, and is determined by your infusion team.

Q4: Can I receive vaccines while on rituximab treatment?
Because rituximab depletes B cells, vaccine responses may be reduced, and live vaccines may be unsafe during and shortly after therapy. Where possible, important vaccinations are given before starting rituximab therapy. You should always discuss the timing and type of any vaccine with your specialist before receiving it.

Q5: Will my B cells recover after finishing Reditux 500 mg?
After completing rituximab treatment, B-cell counts generally recover gradually over months, but the time course varies between individuals and depends on cumulative dose, concomitant therapies and underlying disease. Your specialist may monitor B-cell counts and immunoglobulin levels and will advise you on infection precautions and vaccine planning during and after recovery.

Invista 100 mg Dasatinib Tablets (1 pack / 10 tabs)

At a Glance

Generic Name: Dasatinib

Brand Name: Invista

Strength & Pack Size: 100 mg per tablet; 1 pack / 10 tablets

Dosage Form & Route: Oral tablet, swallowed whole with water

Therapeutic Class: Tyrosine kinase inhibitor (BCR-ABL/Src family), targeted anticancer therapy

Primary Indication: Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)

Usual Adult Dose: Often 100 mg once daily in adult CML regimens, but dose and schedule are defined by your specialist

Prescription Status: Prescription-only medicine

Storage: Store below 25-30 °C in the original blister pack, protect from moisture and keep out of reach of children

Product Description

Invista 100 mg contains dasatinib, an oral targeted medicine used in certain blood cancers driven by abnormal tyrosine kinase signaling. It is prescribed for Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) and for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in treatment settings where a specialist decides that dasatinib is appropriate. This pack provides 100 mg tablets supplied as 1 pack / 10 tablets, intended to support a planned treatment schedule and routine monitoring as directed by your hematology-oncology team.

Dasatinib is a prescription-only anticancer medicine and is not suitable for self-selection. In CML and Ph+ ALL care, your hematology-oncology team considers disease phase, prior therapies, comorbidities, infection history, bleeding risk, and potential drug interactions before choosing a regimen. Some patients receive dasatinib as first-line therapy, while others receive it after resistance or intolerance to another tyrosine kinase inhibitor, and the goals of treatment are always individualized.

Generic Meds Mart supplies Invista 100 mg dasatinib tablets in original manufacturer packaging sourced through licensed channels. The carton and blister typically show the brand name, strength, active ingredient, batch number, and expiry date so your clinic or pharmacy can verify product identity on receipt. Orders are processed with secure checkout in USD and shipped in discreet outer packaging to support privacy, with international delivery options designed to help patients coordinate refills with specialist monitoring. If you are comparing options, ask your clinic to confirm the correct strength and pack size before ordering and avoid making decisions based only on dasatinib price.

Key Uses

Invista 100 mg dasatinib is used to treat Philadelphia chromosome-positive chronic myeloid leukemia, including chronic phase and other phases when a specialist recommends a dasatinib-based approach. CML is a myeloproliferative cancer associated with the BCR-ABL fusion protein, and long-term disease control often depends on consistent kinase inhibition together with scheduled laboratory monitoring.

Dasatinib is also used in Philadelphia chromosome-positive acute lymphoblastic leukemia, usually as part of a specialist-led protocol that may include additional medicines. The exact indication, combination strategy, and duration are individualized, and your team will explain how response is assessed, how often blood tests are required, and which symptoms should prompt urgent contact.

How Dasatinib Works in Chemotherapy

Dasatinib inhibits multiple tyrosine kinases, including BCR-ABL and members of the Src family, which are involved in signaling pathways that help malignant cells survive and proliferate. In Philadelphia chromosome-positive disease, BCR-ABL acts like a continuously active switch that drives abnormal cell growth. By blocking this signaling, dasatinib can reduce the growth advantage of leukemic cells and help bring blood counts and disease markers under control over time when therapy is taken consistently as prescribed.

Because dasatinib is a targeted inhibitor rather than a classic DNA-damaging chemotherapy, its effects and risks differ from many older regimens. Treatment still requires careful monitoring, and side effects can involve blood counts, fluid retention, bleeding tendency, or infections depending on individual risk factors and concomitant medicines. Your specialist balances expected benefit with safety and may adjust therapy based on laboratory trends, symptoms, and known interactions.

Dosage & Administration

Invista 100 mg tablets are taken by mouth exactly as prescribed by your hematology-oncology specialist. In adult CML regimens, dasatinib is often taken once daily, but the appropriate dose can differ depending on diagnosis, disease phase, response, tolerability, and other medicines. Swallow the tablet whole with water and take it at about the same time each day unless your clinic instructs otherwise.

Drug interactions can be clinically important with dasatinib. Certain strong CYP3A inhibitors or inducers may change drug exposure, and some acid-reducing medicines may need careful timing or alternatives because they can affect absorption. Always share a complete list of prescription medicines, over-the-counter products, and supplements with your specialist and pharmacist. If a dose is missed, follow your clinic’s instructions and do not take extra tablets to compensate unless your care team explicitly instructs you to do so.

Precautions

Dasatinib can cause myelosuppression, meaning reductions in white blood cells, red blood cells, and platelets. Regular blood tests are required, and dose interruptions or adjustments may be needed if cytopenias become significant. Contact your clinic urgently if you develop fever, chills, persistent sore throat, unusual bruising or bleeding, or severe fatigue, as these can signal infection, bleeding, or other complications that need prompt assessment.

Fluid retention is an important risk with dasatinib and may present as swelling, rapid weight gain, or pleural effusion with new or worsening cough or breathing difficulty. Some patients may experience pulmonary arterial hypertension, which requires specialist evaluation. Dasatinib may also increase bleeding risk, especially when combined with anticoagulants or antiplatelet medicines. Pregnancy should be avoided during treatment, and contraception planning should be discussed with your specialist before starting therapy.

Dasatinib Side Effects

Common side effects

Common dasatinib side effects may include headache, diarrhea, nausea, fatigue, muscle or joint aches, skin rash, and mild bruising. Blood tests may show anemia, neutropenia, or thrombocytopenia that require monitoring and, in some cases, supportive care or dose modification. Many effects are manageable when identified early, so report persistent or worsening symptoms rather than adjusting treatment on your own.

Serious side effects

Serious side effects require urgent medical attention and can include severe infection, heavy or unusual bleeding, marked shortness of breath, chest pain, or signs of significant fluid retention such as pleural effusion. Severe drops in blood counts, severe skin reactions, and clinically important liver test abnormalities can also occur. If you experience high fever, severe breathing difficulty, fainting, coughing up blood, or rapidly worsening symptoms, seek emergency care and inform clinicians that you are taking dasatinib.

Storage

Store Invista 100 mg below 25-30 °C, protected from moisture and direct heat, and keep the tablets in the original blister pack until use. Keep all medicines out of reach of children. Do not use the tablets after the expiry date printed on the carton or blister, and follow local guidance or your pharmacist’s advice for safe disposal of unused tablets.

Why Buy from Generic Meds Mart

Generic Meds Mart supports access and logistics for specialty medicines such as Invista 100 mg dasatinib tablets. Products are supplied in original packaging from licensed channels with batch and expiry information to support verification by pharmacies and clinics, and discreet packaging helps protect privacy during delivery.

Prices are shown in USD to support planning, orders are processed with secure checkout, and worldwide delivery options can help patients coordinate refills with monitoring schedules and specialist visits. Generic Meds Mart does not replace your treating doctor; decisions about whether dasatinib is appropriate, how long to use it, and how to manage side effects must be made by qualified healthcare professionals.

Order Now

Before you buy Invista 100 mg online from Generic Meds Mart, you should have a confirmed diagnosis of Ph+ CML or Ph+ ALL and a treatment plan agreed with your hematology-oncology specialist. Your care team will advise which monitoring tests are needed and how often, and they will review interaction risks with your current medicines so your dasatinib dosage and schedule are clear.

Once your plan is confirmed, select Invista 100 mg (1 pack / 10 tabs), add it to your cart, and complete secure checkout in USD. Do not start therapy on your own, and do not stop or change dosing without medical guidance. If you develop concerning symptoms such as heavy bleeding, fever, signs of serious infection, chest pain, or persistent breathing problems, seek urgent medical care and inform clinicians that you are taking dasatinib.

FAQ about Invista (Dasatinib)

Q1: What is Invista 100 mg used for?

Invista 100 mg contains dasatinib, a tyrosine kinase inhibitor used in Philadelphia chromosome-positive chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia when prescribed by a hematology-oncology specialist.

Q2: How should I take Invista 100 mg tablets?

Invista tablets are taken by mouth on a schedule defined by your specialist. Swallow the tablet whole with water and take it consistently as directed, with or without food depending on your clinic’s instructions.

Q3: Can Invista interact with other medicines?

Yes. Some medicines can change dasatinib exposure, and acid-reducing products may require careful timing or alternatives. Share a full list of medicines and supplements with your specialist so safe timing can be planned.

Q4: What should I do if I miss a dose?

If you miss a dose, follow your clinic’s instructions and do not take extra tablets to compensate unless your specialist tells you to. If you are unsure, contact your prescribing team for guidance.

Q5: What monitoring is usually needed during treatment?

Monitoring commonly includes blood counts and clinical checks for infection, bleeding symptoms, and breathing issues related to fluid retention, with frequency defined by your specialist based on your treatment plan.